These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 35467423)
1. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy. Hoffmann M; Sidarovich A; Arora P; Krüger N; Nehlmeier I; Kempf A; Graichen L; Winkler MS; Niemeyer D; Goffinet C; Drosten C; Schulz S; Jäck HM; Pöhlmann S mBio; 2022 Jun; 13(3):e0036422. PubMed ID: 35467423 [TBL] [Abstract][Full Text] [Related]
2. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818 [TBL] [Abstract][Full Text] [Related]
3. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Puray-Chavez M; LaPak KM; Schrank TP; Elliott JL; Bhatt DP; Agajanian MJ; Jasuja R; Lawson DQ; Davis K; Rothlauf PW; Liu Z; Jo H; Lee N; Tenneti K; Eschbach JE; Shema Mugisha C; Cousins EM; Cloer EW; Vuong HR; VanBlargan LA; Bailey AL; Gilchuk P; Crowe JE; Diamond MS; Hayes DN; Whelan SPJ; Horani A; Brody SL; Goldfarb D; Major MB; Kutluay SB Cell Rep; 2021 Jul; 36(2):109364. PubMed ID: 34214467 [TBL] [Abstract][Full Text] [Related]
4. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection. Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417 [TBL] [Abstract][Full Text] [Related]
5. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related]
6. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection. Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS J Biol Chem; 2021; 296():100759. PubMed ID: 33965375 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. Kuba K; Yamaguchi T; Penninger JM Front Immunol; 2021; 12():732690. PubMed ID: 35003058 [TBL] [Abstract][Full Text] [Related]
9. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545 [TBL] [Abstract][Full Text] [Related]
13. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Kim YJ; Jang US; Soh SM; Lee JY; Lee HR Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling. Karthika T; Joseph J; Das VRA; Nair N; Charulekha P; Roji MD; Raj VS Cells; 2021 Jul; 10(7):. PubMed ID: 34359983 [TBL] [Abstract][Full Text] [Related]
16. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Baggen J; Jacquemyn M; Persoons L; Vanstreels E; Pye VE; Wrobel AG; Calvaresi V; Martin SR; Roustan C; Cronin NB; Reading E; Thibaut HJ; Vercruysse T; Maes P; De Smet F; Yee A; Nivitchanyong T; Roell M; Franco-Hernandez N; Rhinn H; Mamchak AA; Ah Young-Chapon M; Brown E; Cherepanov P; Daelemans D Cell; 2023 Aug; 186(16):3427-3442.e22. PubMed ID: 37421949 [TBL] [Abstract][Full Text] [Related]
17. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139 [TBL] [Abstract][Full Text] [Related]
18. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823 [TBL] [Abstract][Full Text] [Related]
19. The TRAF3-DYRK1A-RAD54L2 complex maintains ACE2 expression to promote SARS-CoV-2 infection. Mao D; Liu S; Phan AT; Renner S; Sun Y; Wang TT; Zhu Y J Virol; 2024 May; 98(5):e0034724. PubMed ID: 38651897 [TBL] [Abstract][Full Text] [Related]
20. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]